• We are a fully integrated vaccine company with two travel vaccines on the market.

  • Dedicated to innovation in vaccine research and development.

  • Valneva’s R&D focuses on vaccines addressing high unmet medical needs.

  • Valneva covers the full value chain from research to market.

Welcome to Valneva
A fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines.


Download 2017 Valneva Annual Business Report

December 17, 2018
Valneva Initiates Phase 2 Clinical Development for its Lyme Disease Vaccine Candidate

Read more

— Stock information


— November 19, 2018
Emergent BioSolutions and Valneva Report Positive Phase 1 Results for their Vaccine Candidate Against the Zika Virus

Read more
— Financial Calendar

February 21, 2019
Revenues 2018

March 21, 2019
2018 Financial Statements

See all dates


News in German


Images, presentations and videos


learn more
play video Company Video

– Upcoming conferences

January 7-10, 2019
Investor meetings during Annual JP Morgan healthcare conference, San Francisco

April 15-17, 2019
World Vaccine Congress, Washington D.C.
Please update your browser...